Long-term follow-up data from the COMET trial show a sustained improvement in lung and motor function with avalglucosidase alfa (AVAL) in patients with late-onset Pompe disease, according to data presented at WMS 2022.
COMET was a phase 3 randomized trial that compared the efficacy and safety of AVAL with alglucosidase alfa (ALGLU). Both therapies were given at a dose of 20 mg/kg every 2 weeks for 49 weeks.